…
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies that inhibit galectin-3 to address fibrotic and inflammatory diseases. Long-term growth may be supported by advancing its lead galectin-3 inhibitor through development, pursuing partnerships or licensing, and expanding into additional fibrotic indications, which could appeal to investors seeking targeted antifibrotic exposure.
Principal risks include clinical and regulatory failure, lack of commercial revenues creating financing and dilution pressure, and competition from other antifibrotic and NASH programs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M |
| Net income | -30.84M | -47.05M | -41.07M | -39.20M | -30.98M |
| Selling general administrative | 5.79M | 5.86M | 5.90M | 6.62M | 6.36M |
| Selling and marketing expenses | - | - | 0.04M | - | - |
| Gross profit | - | -0.04M | -0.03M | - | - |
| Reconciled depreciation | 0.05M | 0.04M | 0.03M | 0.03M | 0.04M |
| Ebit | -23.51M | -41.51M | -38.27M | -38.35M | -30.18M |
| Ebitda | -23.45M | -41.47M | -38.24M | -38.30M | -30.18M |
| Depreciation and amortization | 0.05M | 0.04M | 0.03M | 0.05M | 0.00M |
| Operating income | -20.09M | -42.43M | -38.07M | -38.35M | -30.18M |
| Other operating expenses | 20.09M | 42.43M | 38.07M | 38.35M | 30.18M |
| Interest expense | 7.33M | 5.54M | 2.79M | 1.03M | 0.49M |
| Interest income | 0.13M | 0.34M | 0.19M | 0.05M | 0.00M |
| Net interest income | -7.20M | -5.20M | -2.07M | -0.98M | -0.49M |
| Income tax expense | - | - | -2.99M | 0.42M | 0.45M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 20.09M | 42.40M | 38.04M | 38.35M | 30.18M |
| Cost of revenue | - | 0.04M | 0.03M | - | - |
| Total other income expense net | -10.75M | -4.61M | -2.99M | -0.42M | -0.35M |
| Net income from continuing ops | -30.84M | -47.05M | -41.70M | -38.78M | -30.53M |
| Net income applicable to common shares | - | - | - | -38.87M | -30.70M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 19.53M | 17.50M | 28.20M | 21.29M | 41.83M |
| Other current assets | 1.72M | 2.13M | 2.05M | 1.96M | 2.17M |
| Total liab | 145.73M | 120.56M | 88.44M | 55.20M | 40.93M |
| Total stockholder equity | -126.19M | -103.07M | -60.24M | -33.92M | 0.89M |
| Other current liab | 4.76M | 8.62M | 9.14M | 9.08M | 7.22M |
| Common stock | 0.07M | 0.06M | 0.06M | 0.06M | 0.06M |
| Capital stock | 2.28M | 2.29M | 2.28M | 2.29M | 2.31M |
| Retained earnings | -432.55M | -401.57M | -354.37M | -309.57M | -270.69M |
| Other liab | - | - | - | 0.07M | - |
| Other assets | - | - | 0.00M | 0.73M | - |
| Cash | 17.72M | 15.12M | 25.66M | 18.59M | 39.65M |
| Total current liabilities | 8.03M | 35.41M | 15.68M | 13.01M | 9.03M |
| Current deferred revenue | - | -6.68M | 0.06M | - | - |
| Net debt | 116.02M | 91.12M | 46.15M | 21.28M | -10.59M |
| Short term debt | 0.02M | 21.14M | 0.05M | 0.04M | 0.01M |
| Short long term debt | - | 21.12M | - | - | - |
| Short long term debt total | 133.74M | 106.25M | 71.81M | 39.87M | 29.06M |
| Other stockholder equity | 304.07M | 296.22M | 293.57M | 273.87M | 269.81M |
| Property plant equipment | - | - | - | - | 0.01M |
| Total current assets | 19.44M | 17.25M | 27.71M | 20.55M | 41.82M |
| Net tangible assets | - | - | - | -34.43M | 0.37M |
| Long term debt | 133.74M | 85.11M | 71.74M | 39.83M | 29.05M |
| Accounts payable | 3.25M | 5.66M | 6.43M | 3.89M | 1.80M |
| Accumulated other comprehensive income | - | - | -1.72M | - | - |
| Non currrent assets other | 0.10M | 0.24M | 0.44M | 0.73M | 0.01M |
| Non current assets total | 0.10M | 0.24M | 0.49M | 0.73M | 0.01M |
| Capital lease obligations | 0.02M | 0.02M | 0.05M | 0.04M | 0.01M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to liabilities | - | - | - | 4.24M | 3.69M |
| Net borrowings | 21.00M | 30.00M | 30.00M | 10.00M | 30.00M |
| Total cash from financing activities | 26.48M | 31.23M | 40.03M | 10.00M | 36.81M |
| Change to operating activities | - | - | - | 0.72M | 0.07M |
| Net income | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M |
| Change in cash | 2.60M | -10.54M | 7.07M | -21.06M | 12.51M |
| Begin period cash flow | 15.12M | 25.66M | 18.59M | 39.65M | 27.14M |
| End period cash flow | 17.72M | 15.12M | 25.66M | 18.59M | 39.65M |
| Total cash from operating activities | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M |
| Issuance of capital stock | 3.23M | 0.00M | - | 0.00M | 6.81M |
| Depreciation | 0.05M | 0.04M | 0.03M | 0.03M | 0.04M |
| Dividends paid | 0.14M | 0.09M | 0.12M | -0.10M | -0.17M |
| Sale purchase of stock | 0.67M | 0.84M | 0.67M | 0.90M | - |
| Other cashflows from financing activities | 0.14M | 0.09M | 10.03M | 8.30M | 30.17M |
| Change to netincome | - | - | - | 2.72M | 2.43M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.61M | 2.28M | 4.68M | 4.97M | 3.75M |
| Stock based compensation | 1.66M | 2.45M | 2.26M | 2.87M | 2.08M |
| Other non cash items | 4.64M | 0.51M | 1.13M | -0.15M | 0.49M |
| Free cash flow | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| GALT Galectin Therapeutics Inc |
-0.09 2.87% |
3.05 | - | 4.54 | - | 207.70 | -4.04 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071
678 620 3186
9
| Name | Title | Year Born |
|---|---|---|
| Mr. Joel Lewis | Pres, CEO & Director | 1970 |
| Mr. Jack W. Callicutt CPA, CPA | CFO, Treasurer & Corp. Sec. | 1967 |
| Dr. Pol F. Boudes M.D., Ph.D. | Chief Medical Officer | 1957 |
| Robert Tritt | Gen. Counsel | NA |
| Ms. Beth Knowles | Exec. Assistant & Officer Mang. | NA |
| Mr. Joel Lewis | President, CEO & Director | 1970 |
| Mr. Jack W. Callicutt CPA | CFO, Treasurer & Corporate Secretary | 1967 |
| Robert Tritt | General Counsel | NA |
| Mr. Jeff Katstra | Head of CMC & Pharmaceutical Development | NA |
| Ms. Beth Knowles | Executive Assistant & Officer Manager | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.